

In the Claims:

The following listing of claims supersedes all previous versions. Please amend the claims as follows:

1. (Currently amended) A method of treating a mammal having diminished renal function, comprising administering to the mammal a therapeutically effective amount of an anti-TGF- β antibody ~~a TGF- β antagonist~~ and a therapeutically effective amount of an ACE inhibitor ~~a RAAS antagonist~~ in the amounts and for a period of time sufficient to treat renal insufficiency.

2. (Currently amended) A method of slowing loss of renal function in a mammal having a renal disorder, comprising administering to the mammal a therapeutically effective amount of an anti-TGF- β antibody ~~a TGF- β antagonist~~ and a therapeutically effective amount of an ACE inhibitor ~~a RAAS antagonist~~ thereby slowing the loss of the renal function.

3. (Previously presented) The method of claim 2, wherein the loss of renal function which is slowed is a renal function selected from the group consisting of pressure filtration, selective reabsorption, tubular secretion, and systemic blood pressure regulation.

4. (Cancelled)

5. (Currently amended) The method of claim ~~[[4]]~~ 1 or 2, wherein the ACE inhibitor is lisinopril.

6. (Cancelled)
7. (Currently amended) The method of claim ~~[[6]]~~ 1 or 2, wherein the anti-TGF- β antibody ~~or the anti-TGF- β receptor antibody~~ is human or humanized.
8. (Currently amended) The method of claim ~~[[6]]~~ 1 or 2, wherein the anti-TGF- β antibody specifically binds to TGF- β 1, TGF- β 2, and TGF- β 3.
9. (Withdrawn, currently amended) The method of claim ~~[[6]]~~ 1 or 2, wherein the anti-TGF- β antibody specifically binds to TGF- β 1 and TGF- β 2.
10. (Currently amended) The method of claim 8, wherein the antibody is 1D11 or an antibody comprising CDR sequences identical to those of 1D11, wherein 1D11 is the antibody deposited with the American Type Culture Collection (ATCC) under Designation No. HB 9849 ~~a derivative thereof~~.
11. (Withdrawn, currently amended) The method of claim ~~[[6]]~~ 1 or 2, wherein the antibody specifically binds to TGF- β 1.
12. (Withdrawn) The method of claim 11, wherein the antibody is CAT192 or a derivative thereof.
13. (Original) The method of claim 1 or 2, wherein the mammal is human.
14. (Original) The method of claim 1 or 2, wherein the mammal is diabetic.
15. (Original) The method of claim 1 or 2, wherein the mammal is hypertensive.

16. (Currently amended) The method of claim 1 or 2, wherein the anti-TGF- β antibody ~~TGF- β antagonist~~ and the ACE inhibitor ~~RAAS antagonists~~ are administered concomitantly for more than 2 weeks.

17. (Currently amended) A method of improving renal function in a mammal having diminished renal function, ~~the method~~ comprising administering to the mammal a therapeutically effective amount of an anti-TGF- β antibody ~~a TGF- β antagonist~~ and a therapeutically effective amount of an ACE inhibitor ~~a RAAS antagonist~~ ~~to the mammal~~ in the amounts and for a time period sufficient to improve the renal function.

18. (Previously presented) The method of claim 17, wherein the renal function is improved by at least 10%.

19. (Original) The method of claim 17, wherein the mammal has renal insufficiency.

20. (Withdrawn) The method of claim 17, wherein the mammal has renal failure.

21. (Withdrawn) The method of claim 17, wherein the mammal has end-stage renal disease.

22. (Original) The method of claim 17, wherein the mammal is diabetic.

23. (Original) The method of claim 17, wherein the renal function which is improved is selected from the group consisting of pressure filtration, selective reabsorption, and tubular secretion.

24. (Original) The method of claim 17, wherein proteinuria is reduced by at least 10%.

25. (Original) The method of claim 17, wherein urinary albumin excretion is reduced by at least 10%.

26. (Cancelled)

27. (Withdrawn) The method of claim 26, wherein the ACE inhibitor is enalapril.

28. (Cancelled)

29. (Currently amended) The method of claim ~~[[28]]~~ 17, wherein the anti-TGF- β antibody ~~or the anti-TGF- β receptor antibody~~ is human or humanized.

30. (Currently amended) The method of claim ~~[[28]]~~ 17, wherein the anti-TGF- β antibody specifically binds to TGF- β 1, TGF- β 2, and TGF- β 3.

31. (Withdrawn, currently amended) The method of claim ~~[[28]]~~ 17, wherein the anti-TGF- β antibody specifically binds to TGF- β 1 and TGF- β 2.

32. (Currently amended) The method of claim ~~[[28]]~~ 17, wherein the TGF- β antibody is 1D11 or a humanized or human antibody comprising CDR sequences identical to those of 1D11, wherein 1D11 is the antibody deposited with the American Type Culture Collection (ATCC) under Designation No. HB 9849 ~~derivative thereof~~.

33. (Currently amended) The method of claim ~~[[28]]~~ 17, wherein the TGF- β antibody specifically binds to TGF- β 1.

34. (Withdrawn) The method of claim 33, wherein the TGF- β antibody is CAT192 or a derivative thereof.
35. (Original) The method of claim 17, wherein the mammal is human.
36. (Cancelled)
37. (Original) The method of claim 17, wherein the mammal is hypertensive.
38. (Currently amended) The method of claim 17, wherein the anti-TGF- β antibody ~~TGF- β antagonist~~ and the ACE inhibitor ~~RAAS antagonists~~ are administered concomitantly for more than 2 weeks.
39. (New) The method of claim 10, wherein the antibody comprising CDR sequences identical to those of 1D11 is a humanized or human antibody, wherein 1D11 is the antibody deposited with the American Type Culture Collection (ATCC) under Designation No. HB 9849 .